Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401

Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401

MT newswireMT newswire2026/10/08 18:25

02:25 PM EDT, 10/08/2026 (MT Newswires) -- (Updates with the stock move in the headline and first paragraph and the Wells Fargo upgrade in the last.) Editas Medicine (EDIT) shares rose 3.1% in Thursday trading after the company received approval in Australia to initiate the phase 1/2 clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia. The trial won approval from Australia's Human Research Ethics Committee and completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration, Editas said. The study has also been submitted for review in New Zealand, and if approved, patients in both countries will be eligible to enroll, the company said. Editas said new preclinical data demonstrating durability of LDL-C reduction with EDIT-401 will be released at the American Heart Association Scientific Sessions from Nov. 6 to Nov. 9. Wells Fargo upgraded Editas to overweight from equal weight with a $6 price target. Price: 2.84, Change: +0.09, Percent Change: +3.09

02:25 PM EDT, 10/08/2026 (MT Newswires) -- (Updates with the stock move in the headline and first paragraph and the Wells Fargo upgrade in the last.) Editas Medicine (EDIT) shares rose 3.1% in Thursday trading after the company received approval in Australia to initiate the phase 1/2 clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia. The trial won approval from Australia's Human Research Ethics Committee and completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration, Editas said. The study has also been submitted for review in New Zealand, and if approved, patients in both countries will be eligible to enroll, the company said. Editas said new preclinical data demonstrating durability of LDL-C reduction with EDIT-401 will be released at the American Heart Association Scientific Sessions from Nov. 6 to Nov. 9. Wells Fargo upgraded Editas to overweight from equal weight with a $6 price target. Price: 2.84, Change: +0.09, Percent Change: +3.09
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

DayOne suspends $5 billion IPO as AI data center valuation comes under scrutiny

Data center operator DayOne has shelved its $5 billion IPO due to concerns about the valuation of AI data centers; its largest client is ByteDance, the Chinese parent company of TikTok.

智通财经•2026/11/20 07:38